Free Trial

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 18 of 20

 
 

Edgewise Therapeutics (NASDAQ:EWTX)

Edgewise Therapeutics logoEdgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. Read More 
 
Trailing Twelve Months EPS: ($1.50)
2024 EPS Estimate: ($1.46)
2025 EPS Estimate: ($1.81)

Current Stock Price
$32.08
Consensus Rating
Buy
Ratings Breakdown
6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$39.50 (23.1% Upside)

 

The Great AI-Energy Collision (Ad)

The biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector.

Get the full story here, while you still can.